INSIDE PHARMA

Since I started writing Inside Pharma in January 2021, my aim has been the same: to name the structural failures in how this industry outsources, governs, and manufactures — and to do it without flinching. That hasn’t changed. But how I’m doing it is about to. Starting this coming Friday, I’m pausing new issues of Inside Pharma. The archive isn’t going anywhere — everything I’ve published here stays live and searchable, and I’d encourage you to keep dipping into it.

[This was first sent 22nd January 2022. The Oxford BioMedica link returns ‘Page not Found’ - hmmmmmmmm] Philip and Lois are tireless medical freedom fighters, and I am honoured that they asked me to provide an expert witness statement on the SARS-CoV-2 injections. Many of you will know, there is an ongoing criminal investigation, with litigation on the cards as things progress. I thought is may be useful to summaries the main findings and conclusions in my own expert report.

INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

[This goes back to February 2022 - beggars belief that Brook is still fighting her corner when she was so good at what she did] For those who don’t know who Brook Jackson is, take a look at this YouTube Video Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial On September 7, 2020, Brook Jackson began her employment with Ventavia Research Group (“Ventavia”) as a Regional Director. Ventavia is not owned by Pfizer.

[this was first posted August 22, 2023 -nothing has changed since - the book was published by Wiley August 2025] The good news is that I have signed a book contract with the New Jersey based published Wiley. It’s with Wiley’s Academic Publishing Group, so it has to be factual and, of course, educational.

Share This is self-explanatory and it will only take just over 2 minutes out of your life: This explains a way out of the big pharma mess! Leave a comment

INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. The below is taken from a current LinkedIn post. As you read this, remember what I’ve been saying for a very long time - Big Pharma is on the verge of bankruptcy. That was the motive behind the SARS-CoV-2 injections that damaged millions, killed untold numbers, and has driven turbo-cancers to previously unheard of heights.

“During a nearly 30-year career at GlaxoSmithKline (GSK), including a position as head of research and development, Slaoui oversaw the development of a number of vaccines, including vaccines to prevent cervical cancer, gastroenteritis, shingles, pneumococcal disease, and Ebola. Slaoui spent 27 years researching a vaccine for malaria. Although largely eradicated in developed countries, malaria still kills more than 400,000 people annually — most of them children in sub-Saharan Africa.

Hoping we can have some fun today, while learning about what’s been going on. Below are some links that should lead you to interesting places: 2015: Joint Committee on Vaccination and Immunisation: Protocols for vaccine manufacturer engagement with JCVI sub-committees (JCVI met with vaccine manufacturers) 2016: Office for Life Sciences spend on work to support the Accelerated Access Review (OLS pushing for ‘accelerated’ regulatory approvals from MHRA.

This is an interview from earlier today, posted on LinkedIn: In our latest episode of Out of the Lab: Operationalizing Cell and Gene Therapy, biopharma supply chain expert Hedley Rees pulled back the curtain on a concept that early-stage biotech founders ignore at their own peril: Post-Contractual Moral Hazard. The second the ink dries on a master services agreement, the balance of power shifts dramatically from the asset owner to the contract manufacturer.